EMA gets to work on bringing more advanced therapies to market
This article was originally published in RAJ Devices
The European Medicines Agency's Committee for Advanced Therapies will look at how the regulatory framework around advanced therapies such as gene therapy and regenerative medicine can be made more accessible for small and medium-sized firms, academia, patient groups, hospitals, charity foundations and trusts that develop advanced therapies1,2. The EMA admits that the current framework is very complex and that many SMEs and academics lack the financial and human resources to negotiate it. Often developers do not have the resources to bring their products, which are sometimes fairly mature, to regulatory standards, says the EMA.
You may also be interested in...
Canada has announced new restrictions on exports to help mitigate the impact of measures in the US to lower medicine prices there.
In the wake of the COVID-19 pandemic and the ensuing economic fallout, pharmaceutical companies could face a range of measures designed to cut government spending on medicines. From relaxing intellectual property rights to delaying reimbursement, In Vivo examines what might be in store for industry.
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.